Methods and compositions related to inhibition of viral entry

Patent metadata

Field	Value
Publication number	US-2016354428-A1
Application number	US-201615171753-A
Country	US
Kind code	A1
Filing date	Jun 2, 2016
Priority date	Feb 8, 2007
Publication date	Dec 8, 2016
Grant date	—

Abstract

Disclosed are compositions and methods for inhibiting viral entry.

First claim

1 .- 104 . (canceled)

105 . A method for inhibiting viral entry into a cell, comprising exposing the virus to a composition, the composition comprising at least one peptide that interacts with the N-trimer pocket of a viral transmembrane protein, wherein the at least one peptide comprises the amino acid sequence of SEQ ID NO: 36,
thereby inhibiting viral entry into a cell.

106 . The method of claim 105 , wherein the virus is HIV.

107 . The method of claim 105 , wherein the viral transmembrane protein is HIV gp41.

108 . The method of claim 105 , wherein the composition is a pharmaceutical composition comprising the at least one peptide and a pharmaceutically acceptable carrier.

109 . A method of treating a viral infection in a subject comprising administering to the subject an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising (a) at least one peptide that interacts with the N-trimer pocket of a viral transmembrane protein, wherein the at least one peptide comprises the amino acid sequence of SEQ ID NO: 36, and (b) a pharmaceutically acceptable carrier.

110 . The method of claim 109 , wherein the pharmaceutical composition is administered in conjunction with at least one further antiviral agent.

111 . The method of claim 110 , wherein the at least one further antiviral agent is selected from the group consisting of a viral replication inhibitor, a viral protease inhibitor, a viral reverse transcriptase inhibitor, a viral entry inhibitor, a viral integrase inhibitor, a viral Rev inhibitor, a viral Tat inhibitor, a viral Nef inhibitor, a viral Vpr inhibitor, a viral Vpu inhibitor, and a viral Vif inhibitor.

112 . The method of claim 109 , wherein the at least one peptide is linked to at least one other peptide.

113 . The method of claim 112 , wherein a crosslinker is used to multimerize the peptides.

114 . The method of claim 113 , wherein the crosslinker is PEG.

115 . The method of claim 112 , wherein the peptides are crosslinked into branched structures.

116 . The method of claim 112 , wherein the N-termini of the peptides are crosslinked.

117 . The method of claim 112 , wherein the C-termini of the peptides are crosslinked.

118 . The method of claim 112 , wherein the N-terminus of one peptide and the C-terminus of the other peptide are crosslinked.

119 . The method of claim 109 , wherein the viral transmembrane protein is HIV gp41.

120 . The method of claim 109 , wherein the viral infection is HIV.

121 . The method of claim 109 , wherein the at least one peptide is selected from any one of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 12, 13, 23, 24, 25, 26, 27, 28, and 29, or a fragment thereof.

122 . The method of claim 121 , wherein the at least one peptide is SEQ ID NO: 26, or a fragment thereof.

123 . The method of claim 109 , wherein the at least one peptide is a D-peptide.

124 . The method of claim 122 , wherein the at least one peptide is a D-peptide.

Assignees

• Univ Utah Res Found

Inventors

• Kay Michael S
• Welch Brett D

Classifications

• A61P31/18

  for HIV · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title

• A61K47/55

  the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug · CPC title

• A61K47/641

  Branched, dendritic or hypercomb peptides · CPC title